Program

In-person AND virtual! – We are pioneering a new conference format that will connect in-person and virtual audiences to create a unique experience. Matching the innovation that comes through our members’ work, ISPOR is pushing the boundaries of innovation to design an event that works in today’s quickly changing environment. 

In-person registration included the full virtual experience, and virtual-only attendees will be able to tune into live in-person sessions and/or watch captured in-person sessions on-demand in addition to having a variety of virtual-only sessions to attend.

Budgetary Impact Analysis of Alteplase - Recombinant Tissue Plasminogen Activator (RTPA) - As a Thrombolytic Treatment for Acute Ischemic Stroke in Colombia

Speaker(s)

Lasalvia P
NeuroEconomix, BOGOTA, CUN, Colombia

Presentation Documents

Objectives: to evaluate the potential impact on costs and health outcomes of increasing the proportion of patients with acute ischemic stroke (AIS) who are thrombolyzed with alteplase in Colombia and of reducing the time to initiate treatment.

Methods: We developed a budget impact modal estimating with a 5-year time horizon from the perspective of the third-party payer in Colombia. We obtained epidemiological data from local sources and published studies. We established healthcare resource utilization with base case with local clinical experts and costing was performed with local tariff manuels. Efficacy data was extracted from published literature. We considered three windows for treatment initiation: 0-90, 91-180, and 181-270 minutes. Costs were expressed in US dollars of 2020. (2020, 1 USD = $3,693.36 COP)

Results: The increase in thrombolyzed patients from 10 to 22% would decrease the number of patients with sequelae by 1,721, 2,594 and 1,007 in the ranges of 0-90 minutes, 91-180 and 181-270, respectively. The budget effort required for each of the treatment initiation ranges is of USD$15,525,649(5.5%), USD$16,665,304(5.7%) and USD$16,963,231(7.0%), respectively.

Conclusions: From the perspective evaluated, doubling the number of patients with AIS who are thrombolyzed would lead to reductions in the number of patients with sequelae and would require a budgetary effort of 5.5-7.0%. The early initiation of treatment (0-180minutes) gives an additional benefit in reducing the number of sequelae and a lower budgetary impact than initiation within the last time window (181-270minutes).

Code

EE477

Topic

Economic Evaluation

Topic Subcategory

Budget Impact Analysis

Disease

Cardiovascular Disorders